Show simple item record

dc.contributor.authorTapiainen, V
dc.contributor.authorTaipale, H
dc.contributor.authorTanskanen, A
dc.contributor.authorTiihonen, J
dc.contributor.authorHartikainen, S
dc.contributor.authorTolppanen, A-M
dc.date.accessioned2018-06-18T08:24:41Z
dc.date.available2018-06-18T08:24:41Z
dc.date.issued2018
dc.identifier.urihttps://erepo.uef.fi/handle/123456789/6732
dc.description.abstractObjective To assess the association between benzodiazepine and related drug (BZDR) use and risk of Alzheimer's disease (AD) with cumulative consumption and duration of use based models. Method A nationwide nested case–control study of all Finnish community‐dwelling persons who received clinically verified AD diagnosis in 2005–2011 (N = 70 719) and their matched controls (N = 282 862). AD diagnosis was based on DSM‐IV and NINCDS‐ADRDA criteria. BZDR purchases were extracted from the Prescription Register since 1995. The association between BZDR use and AD was assessed using conditional logistic regression with 5‐year lag time between exposure and outcome. Results Benzodiazepine and related drug use was associated with modestly increased risk of AD (adjusted OR 1.06, 95% CI 1.04–1.08). A dose–response relationship was observed with both cumulative consumption and duration. Adjustment for other psychotropics removed the cumulative dose–response relationship by attenuating the ORs in the highest dose category. Conclusion Benzodiazepine and related drug use in general was associated with modestly increased risk of AD. No major differences were observed between different subcategories of BZDRs (i.e. benzodiazepines, Z drugs, short‐/medium‐acting or long‐acting BZDRs). As dose–response relationship abolished after adjustment for other psychotropics, it is possible that the association may partially be due to antidepressants and/or antipsychotics, or concomitant use of these medications.
dc.language.isoenglanti
dc.publisherWiley
dc.relation.ispartofseriesACTA PSYCHIATRICA SCANDINAVICA
dc.relation.urihttp://dx.doi.org/10.1111/acps.12909
dc.rightsAll rights reserved
dc.subjectAlzheimer
dc.subjectpharmacoepidemiology
dc.subjectrisk factors
dc.subjectdementia
dc.titleThe risk of Alzheimer's disease associated with benzodiazepines and related drugs: a nested case-control study
dc.description.versionfinal draft
dc.contributor.departmentSchool of Pharmacy, Activities
dc.contributor.departmentSchool of Medicine / Clinical Medicine
uef.solecris.id55037802en
dc.type.publicationTieteelliset aikakauslehtiartikkelit
dc.rights.accessrights© John Wiley & Sons A/S
dc.relation.doi10.1111/acps.12909
dc.description.reviewstatuspeerReviewed
dc.relation.issn0001-690X
dc.relation.volume[Epub ahead of print 31 May 2018]
dc.rights.accesslevelopenAccess
dc.type.okmA1
uef.solecris.openaccessEi


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record